PUBLISHER: Grand View Research | PRODUCT CODE: 1726198
PUBLISHER: Grand View Research | PRODUCT CODE: 1726198
The global endobronchial ultrasound biopsy market size is anticipated to reach USD 966.9 million by 2030 and is anticipated to expand at a CAGR of 4.83% during the forecast period, according to a new report by Grand View Research, Inc. This growth can be attributed to the increasing incidence of cancer, advancements in Endobronchial Ultrasound (EBUS) technology, a rising elderly population, a higher occurrence of respiratory diseases, and the growing acceptance of minimally invasive procedures. For instance, the World Health Organization (WHO) estimates that there will be more than 35 million new cancer cases in 2050, representing a 77% rise from the estimated 20 million cases recorded in 2022.
The endobronchial ultrasound biopsy market is also driven by advancements in medical technology and the increasing prevalence of respiratory diseases. EBUS devices are primarily used for diagnosing lung cancer, tuberculosis, and other respiratory disorders, offering a minimally invasive alternative to traditional surgical biopsies. Technological innovations such as high-resolution imaging, AI-assisted navigation, and improved probe designs have further enhanced the precision and efficiency of EBUS procedures. In addition, the shift toward personalized medicine and early detection strategies in oncology has enhanced demand for these devices, as they support targeted diagnostic interventions that improve patient outcomes.
Moreover, the market's growth is also fueled by demographic trends such as the growing geriatric population, which is more vulnerable to respiratory conditions such as COPD and asthma. For instance, according to the U.S. Census Bureau, around 57.88% of the country's population was aged 65 years and above in 2023, accounting for 17.5% of the total population. This geriatric population share is further expected to increase over the forecast period. Furthermore, emerging economies are also witnessing market growth due to their large patient pools affected by air pollution-related respiratory disorders. For instance, countries such as China and India have seen increased adoption of EBUS devices due to high rates of lung cancer linked to poor air quality. Moreover, cost-effectiveness compared to invasive alternatives such as mediastinoscopy has made EBUS attractive for healthcare providers.